PRECAUTIONS O
General O
Prescribing O
BIAXIN O
in O
the O
absence O
of O
a O
proven O
or O
strongly O
suspected O
bacterial B-Not_AE_Candidate
infection I-Not_AE_Candidate
or O
a O
prophylactic O
indication O
is O
unlikely O
to O
provide O
benefit O
to O
the O
patient O
and O
increases O
the O
risk O
of O
the O
development O
of O
drug-resistant O
bacteria O
. O

Clarithromycin O
is O
principally O
excreted O
via O
the O
liver O
and O
kidney O
. O

Clarithromycin O
may O
be O
administered O
without O
dosage O
adjustment O
to O
patients O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
and O
normal O
renal O
function O
. O

However O
, O
in O
the O
presence O
of O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
with O
or O
without O
coexisting O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
decreased O
dosage O
or O
prolonged O
dosing O
intervals O
may O
be O
appropriate O
. O

Clarithromycin O
in O
combination O
with O
ranitidine O
bismuth O
citrate O
therapy O
is O
not O
recommended O
in O
patients O
with O
creatinine B-Not_AE_Candidate
clearance I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
2 I-Not_AE_Candidate
5 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
. O

( O
See O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O

Clarithromycin O
in O
combination O
with O
ranitidine O
bismuth O
citrate O
should O
not O
be O
used O
in O
patients O
with O
a O
history O
of O
acute B-Not_AE_Candidate
porphyria I-Not_AE_Candidate
. O

Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
of I-OSE_Labeled_AE
myasthenia I-OSE_Labeled_AE
gravis I-OSE_Labeled_AE
and O
new O
onset O
of O
symptoms O
of O
myasthenic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
receiving O
clarithromycin O
therapy O
. O

For O
information O
about O
precautions O
of O
other O
drugs O
indicated O
in O
combination O
with O
BIAXIN O
, O
refer O
to O
the O
PRECAUTIONS O
section O
of O
their O
package O
inserts O
. O

Information O
to O
Patients O
Patients O
should O
be O
counseled O
that O
antibacterial O
drugs O
including O
BIAXIN O
should O
only O
be O
used O
to O
treat O
bacterial B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

They O
do O
not O
treat O
viral B-Not_AE_Candidate
infections I-Not_AE_Candidate
( O
e.g. O
, O
the O
common B-Not_AE_Candidate
cold I-Not_AE_Candidate
) O
. O

When O
BIAXIN O
is O
prescribed O
to O
treat O
a O
bacterial B-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
patients O
should O
be O
told O
that O
although O
it O
is O
common O
to O
feel O
better O
early O
in O
the O
course O
of O
therapy O
, O
the O
medication O
should O
be O
taken O
exactly O
as O
directed O
. O

Skipping O
doses O
or O
not O
completing O
the O
full O
course O
of O
therapy O
may O
( O
1 O
) O
decrease O
the O
effectiveness O
of O
the O
immediate O
treatment O
and O
( O
2 O
) O
increase O
the O
likelihood O
that O
bacteria O
will O
develop O
resistance O
and O
will O
not O
be O
treatable O
by O
BIAXIN O
or O
other O
antibacterial O
drugs O
in O
the O
future O
. O

Diarrhea B-OSE_Labeled_AE
is O
a O
common O
problem O
caused O
by O
antibiotics O
which O
usually O
ends O
when O
the O
antibiotic O
is O
discontinued O
. O

Sometimes O
after O
starting O
treatment O
with O
antibiotics O
, O
patients O
can O
develop B-OSE_Labeled_AE
watery I-OSE_Labeled_AE
and I-OSE_Labeled_AE
bloody I-OSE_Labeled_AE
stools I-OSE_Labeled_AE
( O
with O
or O
without O
stomach B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
) O
even O
as O
late O
as O
two O
or O
more O
months O
after O
having O
taken O
the O
last O
dose O
of O
the O
antibiotic O
. O

If O
this O
occurs O
, O
patients O
should O
contact O
their O
physician O
as O
soon O
as O
possible O
. O

BIAXIN O
may O
interact O
with O
some O
drugs O
; O
therefore O
patients O
should O
be O
advised O
to O
report O
to O
their O
doctor O
the O
use O
of O
any O
other O
medications O
. O

BIAXIN O
tablets O
and O
oral O
suspension O
can O
be O
taken O
with O
or O
without O
food O
and O
can O
be O
taken O
with O
milk O
; O
however O
, O
BIAXIN O
XL O
tablets O
should O
be O
taken O
with O
food O
. O

Do O
NOT O
refrigerate O
the O
suspension O
. O

Drug O
Interactions O
Clarithromycin O
use O
in O
patients O
who O
are O
receiving O
theophylline O
may O
be O
associated O
with O
an O
increase O
of O
serum O
theophylline O
concentrations O
. O

Monitoring O
of O
serum O
theophylline O
concentrations O
should O
be O
considered O
for O
patients O
receiving O
high O
doses O
of O
theophylline O
or O
with O
baseline O
concentrations O
in O
the O
upper O
therapeutic O
range O
. O

In O
two O
studies O
in O
which O
theophylline O
was O
administered O
with O
clarithromycin O
( O
a O
theophylline O
sustained-release O
formulation O
was O
dosed O
at O
either O
6.5 O
mg/kg O
or O
12 O
mg/kg O
together O
with O
250 O
or O
500 O
mg O
q12h O
clarithromycin O
) O
, O
the O
steady-state O
levels O
of O
Cmax O
, O
Cmin O
, O
and O
the O
area O
under O
the O
serum O
concentration O
time O
curve O
( O
AUC O
) O
of O
theophylline O
increased O
about O
20 O
% O
. O

Hypotension B-NonOSE_AE
, O
bradyarrhythmias B-NonOSE_AE
, O
and O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
have O
been O
observed O
in O
patients O
receiving O
concurrent O
verapamil O
, O
belonging O
to O
the O
calcium O
channel O
blockers O
drug O
class O
. O

Concomitant O
administration O
of O
single O
doses O
of O
clarithromycin O
and O
carbamazepine O
has O
been O
shown O
to O
result O
in O
increased O
plasma O
concentrations O
of O
carbamazepine O
. O

Blood O
level O
monitoring O
of O
carbamazepine O
may O
be O
considered O
. O

When O
clarithromycin O
and O
terfenadine O
were O
coadministered O
, O
plasma O
concentrations O
of O
the O
active O
acid O
metabolite O
of O
terfenadine O
were O
threefold O
higher O
, O
on O
average O
, O
than O
the O
values O
observed O
when O
terfenadine O
was O
administered O
alone O
. O

The O
pharmacokinetics O
of O
clarithromycin O
and O
the O
14-OH-clarithromycin O
were O
not O
significantly O
affected O
by O
coadministration O
of O
terfenadine O
once O
clarithromycin O
reached O
steady-state O
conditions O
. O

Concomitant O
administration O
of O
clarithromycin O
with O
terfenadine O
is O
contraindicated O
. O

( O
See O
CONTRAINDICATIONS O
. O
) O

Clarithromycin O
500 O
mg O
every O
8 O
hours O
was O
given O
in O
combination O
with O
omeprazole O
40 O
mg O
daily O
to O
healthy O
adult O
subjects O
. O

The O
steady-state O
plasma O
concentrations O
of O
omeprazole O
were O
increased O
( O
Cmax O
, O
AUC0-24 O
, O
and O
t1/2increases O
of O
30 O
% O
, O
89 O
% O
, O
and O
34 O
% O
, O
respectively O
) O
, O
by O
the O
concomitant O
administration O
of O
clarithromycin O
. O

The O
mean O
24-hour O
gastric O
pH O
value O
was O
5.2 O
when O
omeprazole O
was O
administered O
alone O
and O
5.7 O
when O
coadministered O
with O
clarithromycin O
. O

Coadministration O
of O
clarithromycin O
with O
ranitidine O
bismuth O
citrate O
resulted O
in O
increased O
plasma O
ranitidine O
concentrations O
( O
57 O
% O
) O
, O
increased O
plasma O
bismuth O
trough O
concentrations O
( O
48 O
% O
) O
, O
and O
increased O
14-hydroxy-clarithromycin O
plasma O
concentrations O
( O
31 O
% O
) O
. O

These O
effects O
are O
clinically O
insignificant O
. O

Simultaneous O
oral O
administration O
of O
BIAXIN O
tablets O
and O
zidovudine O
to O
HIV-infected O
adult O
patients O
may O
result O
in O
decreased O
steady-state O
zidovudine O
concentrations O
. O

Following O
administration O
of O
clarithromycin O
500 O
mg O
tablets O
twice O
daily O
with O
zidovudine O
100 O
mg O
every O
4 O
hours O
, O
the O
steady-state O
zidovudine O
AUC O
decreased O
12 O
% O
compared O
to O
administration O
of O
zidovudine O
alone O
( O
n=4 O
) O
. O

Individual O
values O
ranged O
from O
a O
decrease O
of O
34 O
% O
to O
an O
increase O
of O
14 O
% O
. O

When O
clarithromycin O
tablets O
were O
administered O
two O
to O
four O
hours O
prior O
to O
zidovudine O
, O
the O
steady-state O
zidovudine O
Cmaxincreased O
100 O
% O
whereas O
the O
AUC O
was O
unaffected O
( O
n=24 O
) O
. O

Administration O
of O
clarithromycin O
and O
zidovudine O
should O
be O
separated O
by O
at O
least O
two O
hours O
. O

The O
impact O
of O
co-administration O
of O
clarithromycin O
extended-release O
tablets O
and O
zidovudine O
has O
not O
been O
evaluated O
. O

Simultaneous O
administration O
of O
BIAXIN O
tablets O
and O
didanosine O
to O
12 O
HIV-infected O
adult O
patients O
resulted O
in O
no O
statistically O
significant O
change O
in O
didanosine O
pharmacokinetics O
. O

Following O
administration O
of O
fluconazole O
200 O
mg O
daily O
and O
clarithromycin O
500 O
mg O
twice O
daily O
to O
21 O
healthy O
volunteers O
, O
the O
steady-state O
clarithromycin O
Cminand O
AUC O
increased O
33 O
% O
and O
18 O
% O
, O
respectively O
. O

Steady-state O
concentrations O
of O
14-OH O
clarithromycin O
were O
not O
significantly O
affected O
by O
concomitant O
administration O
of O
fluconazole O
. O

No O
dosage O
adjustment O
of O
clarithromycin O
is O
necessary O
when O
co-administered O
with O
fluconazole O
. O

Ritonavir O
Concomitant O
administration O
of O
clarithromycin O
and O
ritonavir O
( O
n O
= O
22 O
) O
resulted O
in O
a O
77 O
% O
increase O
in O
clarithromycin O
AUC O
and O
a O
100 O
% O
decrease O
in O
the O
AUC O
of O
14-OH O
clarithromycin O
. O

Clarithromycin O
may O
be O
administered O
without O
dosage O
adjustment O
to O
patients O
with O
normal O
renal O
function O
taking O
ritonavir O
. O

Since O
concentrations O
of O
14-OH O
clarithromycin O
are O
significantly O
reduced O
when O
clarithromycin O
is O
co-administered O
with O
ritonavir O
, O
alternative O
antibacterial O
therapy O
should O
be O
considered O
for O
indications O
other O
than O
infections O
due O
to O
Mycobacterium B-Not_AE_Candidate
avium I-Not_AE_Candidate
complex I-Not_AE_Candidate
( O
see O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

Doses O
of O
clarithromycin O
greater O
than O
1000 O
mg O
per O
day O
should O
not O
be O
co-administered O
with O
protease O
inhibitors O
. O

Spontaneous O
reports O
in O
the O
post-marketing O
period O
suggest O
that O
concomitant O
administration O
of O
clarithromycin O
and O
oral O
anticoagulants O
may O
potentiate O
the O
effects O
of O
the O
oral O
anticoagulants O
. O

Prothrombin O
times O
should O
be O
carefully O
monitored O
while O
patients O
are O
receiving O
clarithromycin O
and O
oral O
anticoagulants O
simultaneously O
. O

Digoxin O
is O
a O
substrate O
for O
P-glycoprotein O
( O
Pgp O
) O
and O
clarithromycin O
is O
known O
to O
inhibit O
Pgp O
. O

When O
clarithromycin O
and O
digoxin O
are O
co-administered O
, O
inhibition O
of O
Pgp O
by O
clarithromycin O
may O
lead O
to O
increased O
exposure O
of O
digoxin O
. O

Elevated O
digoxin O
serum O
concentrations O
in O
patients O
receiving O
clarithromycin O
and O
digoxin O
concomitantly O
have O
been O
reported O
in O
post-marketing O
surveillance O
. O

Some O
patients O
have O
shown O
clinical O
signs O
consistent O
with O
digoxin B-NonOSE_AE
toxicity I-NonOSE_AE
, O
including O
potentially O
fatal B-NonOSE_AE
arrhythmias B-NonOSE_AE
. O

Monitoring O
of O
serum O
digoxin O
concentrations O
should O
be O
considered O
, O
especially O
for O
patients O
with O
digoxin O
concentrations O
in O
the O
upper O
therapeutic O
range O
. O

Co-administration O
of O
clarithromycin O
, O
known O
to O
inhibit O
CYP3A O
, O
and O
a O
drug O
primarily O
metabolized O
by O
CYP3A O
may O
be O
associated O
with O
elevations O
in O
drug O
concentrations O
that O
could O
increase O
or O
prolong O
both O
therapeutic O
and O
adverse O
effects O
of O
the O
concomitant O
drug O
. O

Clarithromycin O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
treatment O
with O
other O
drugs O
known O
to O
be O
CYP3A O
enzyme O
substrates O
, O
especially O
if O
the O
CYP3A O
substrate O
has O
a O
narrow O
safety O
margin O
( O
e.g. O
, O
carbamazepine O
) O
and/or O
the O
substrate O
is O
extensively O
metabolized O
by O
this O
enzyme O
. O

Dosage O
adjustments O
may O
be O
considered O
, O
and O
when O
possible O
, O
serum O
concentrations O
of O
drugs O
primarily O
metabolized O
by O
CYP3A O
should O
be O
monitored O
closely O
in O
patients O
concurrently O
receiving O
clarithromycin O
. O

The O
following O
are O
examples O
of O
some O
clinically O
significant O
CYP3A O
based O
drug O
interactions O
. O

Interactions O
with O
other O
drugs O
metabolized O
by O
the O
CYP3A O
isoform O
are O
also O
possible O
. O

Carbamazepine O
and O
Terfenadine O
Increased O
serum O
concentrations O
of O
carbamazepine O
and O
the O
active O
acid O
metabolite O
of O
terfenadine O
were O
observed O
in O
clinical O
trials O
with O
clarithromycin O
. O

Colchicine O
Colchicine O
is O
a O
substrate O
for O
both O
CYP3A O
and O
the O
efflux O
transporter O
, O
P-glycoprotein O
( O
Pgp O
) O
. O

Clarithromycin O
and O
other O
macrolides O
are O
known O
to O
inhibit O
CYP3A O
and O
Pgp O
. O

When O
a O
single O
dose O
of O
colchicine O
0.6 O
mg O
was O
administered O
with O
clarithromycin O
250 O
mg O
BID O
for O
7 O
days O
, O
the O
colchicine O
Cmaxincreased O
197 O
% O
and O
the O
AUC0-âˆžincreased O
239 O
% O
compared O
to O
administration O
of O
colchicine O
alone O
. O

The O
dose O
of O
colchicine O
should O
be O
reduced O
when O
co-administered O
with O
clarithromycin O
in O
patients O
with O
normal O
renal O
and O
hepatic O
function O
. O

Concomitant O
use O
of O
clarithromycin O
and O
colchicine O
is O
contraindicated O
in O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
. O

( O
See O
WARNINGS O
) O
. O

Efavirenz O
, O
Nevirapine O
, O
Rifampicin O
, O
Rifabutin O
, O
and O
Rifapentine O
Inducers O
of O
CYP3A O
enzymes O
, O
such O
as O
efavirenz O
, O
nevirapine O
, O
rifampicin O
, O
rifabutin O
, O
and O
rifapentine O
will O
increase O
the O
metabolism O
of O
clarithromycin O
, O
thus O
decreasing O
plasma O
concentrations O
of O
clarithromycin O
, O
while O
increasing O
those O
of O
14-OH-clarithromycin O
. O

Since O
the O
microbiological O
activities O
of O
clarithromycin O
and O
14-OH-clarithromycin O
are O
different O
for O
different O
bacteria O
, O
the O
intended O
therapeutic O
effect O
could O
be O
impaired O
during O
concomitant O
administration O
of O
clarithromycin O
and O
enzyme O
inducers O
. O

Alternative O
antibacterial O
treatment O
should O
be O
considered O
when O
treating O
patients O
receiving O
inducers O
of O
CYP3A O
. O

Sildenafil O
, O
Tadalafil O
, O
and O
Vardenafil O
Each O
of O
these O
phosphodiesterase O
inhibitors O
is O
primarily O
metabolized O
by O
CYP3A O
, O
and O
CYP3A O
will O
be O
inhibited O
by O
concomitant O
administration O
of O
clarithromycin O
. O

Co-administration O
of O
clarithromycin O
with O
sildenafil O
, O
tadalafil O
, O
or O
vardenafil O
will O
result O
in O
increased O
exposure O
of O
these O
phosphodiesterase O
inhibitors O
. O

Co-administration O
of O
these O
phosphodiesterase O
inhibitors O
with O
clarithromycin O
is O
not O
recommended O
. O

Tolterodine O
The O
primary O
route O
of O
metabolism O
for O
tolterodine O
is O
via O
CYP2D6 O
. O

However O
, O
in O
a O
subset O
of O
the O
population O
devoid O
of O
CYP2D6 O
, O
the O
identified O
pathway O
of O
metabolism O
is O
via O
CYP3A O
. O

In O
this O
population O
subset O
, O
inhibition O
of O
CYP3A O
results O
in O
significantly O
higher O
serum O
concentrations O
of O
tolterodine O
. O

Tolterodine O
1 O
mg O
twice O
daily O
is O
recommended O
in O
patients O
deficient O
in O
CYP2D6 O
activity O
( O
poor O
metabolizers O
) O
when O
co-administered O
with O
clarithromycin O
. O

Triazolobenzodiazepines O
( O
e.g. O
, O
alprazolam O
, O
midazolam O
, O
triazolam O
) O
When O
a O
single O
dose O
of O
midazolam O
was O
co-administered O
with O
clarithromycin O
tablets O
( O
500 O
mg O
twice O
daily O
for O
7 O
days O
) O
, O
midazolam O
AUC O
increased O
174 O
% O
after O
intravenous O
administration O
of O
midazolam O
and O
600 O
% O
after O
oral O
administration O
. O

When O
oral O
midazolam O
is O
co-administered O
with O
clarithromycin O
, O
dose O
adjustments O
may O
be O
necessary O
and O
possible O
prolongation O
and O
intensity O
of O
effect O
should O
be O
anticipated O
. O

Caution O
and O
appropriate O
dose O
adjustments O
should O
be O
considered O
when O
triazolam O
or O
alprazolam O
is O
co-administered O
with O
clarithromycin O
. O

For O
benzodiazepines O
which O
are O
not O
metabolized O
by O
CYP3A O
( O
e.g. O
, O
temazepam O
, O
nitrazepam O
, O
lorazepam O
) O
, O
a O
clinically O
important O
interaction O
with O
clarithromycin O
is O
unlikely O
. O

There O
have O
been O
post-marketing O
reports O
of O
drug O
interactions O
and O
central B-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
( I-NonOSE_AE
CNS I-NonOSE_AE
) I-NonOSE_AE
effects I-NonOSE_AE
( O
e.g. O
, O
somnolence B-NonOSE_AE
and O
confusion B-NonOSE_AE
) O
with O
the O
concomitant O
use O
of O
clarithromycin O
and O
triazolam O
. O

Monitoring O
the O
patient O
for O
increased O
CNS O
pharmacological O
effects O
is O
suggested O
. O

Atazanavir O
Both O
clarithromycin O
and O
atazanavir O
are O
substrates O
and O
inhibitors O
of O
CYP3A O
, O
and O
there O
is O
evidence O
of O
a O
bi-directional O
drug O
interaction O
. O

Following O
administration O
of O
clarithromycin O
( O
500 O
mg O
twice O
daily O
) O
with O
atazanavir O
( O
400 O
mg O
once O
daily O
) O
, O
the O
clarithromycin O
AUC O
increased O
94 O
% O
, O
the O
14-OH O
clarithromycin O
AUC O
decreased O
70 O
% O
and O
the O
atazanavir O
AUC O
increased O
28 O
% O
. O

When O
clarithromycin O
is O
co-administered O
with O
atazanavir O
, O
the O
dose O
of O
clarithromycin O
should O
be O
decreased O
by O
50 O
% O
. O

Since O
concentrations O
of O
14-OH O
clarithromycin O
are O
significantly O
reduced O
when O
clarithromycin O
is O
co-administered O
with O
atazanavir O
, O
alternative O
antibacterial O
therapy O
should O
be O
considered O
for O
indications O
other O
than O
infections O
due O
to O
Mycobacterium B-Not_AE_Candidate
avium I-Not_AE_Candidate
complex I-Not_AE_Candidate
( O
see O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

Doses O
of O
clarithromycin O
greater O
than O
1000 O
mg O
per O
day O
should O
not O
be O
co-administered O
with O
protease O
inhibitors O
. O

Itraconazole O
Both O
clarithromycin O
and O
itraconazole O
are O
substrates O
and O
inhibitors O
of O
CYP3A O
, O
potentially O
leading O
to O
a O
bi-directional O
drug O
interaction O
when O
administered O
concomitantly O
. O

Clarithromycin O
may O
increase O
the O
plasma O
concentrations O
of O
itraconazole O
, O
while O
itraconazole O
may O
increase O
the O
plasma O
concentrations O
of O
clarithromycin O
. O

Patients O
taking O
itraconazole O
and O
clarithromycin O
concomitantly O
should O
be O
monitored O
closely O
for O
signs O
or O
symptoms O
of O
increased O
or O
prolonged O
adverse O
reactions O
. O

Saquinavir O
Both O
clarithromycin O
and O
saquinavir O
are O
substrates O
and O
inhibitors O
of O
CYP3A O
and O
there O
is O
evidence O
of O
a O
bi-directional O
drug O
interaction O
. O

Following O
administration O
of O
clarithromycin O
( O
500 O
mg O
bid O
) O
and O
saquinavir O
( O
soft O
gelatin O
capsules O
, O
1200 O
mg O
tid O
) O
to O
12 O
healthy O
volunteers O
, O
the O
steady-state O
saquinavir O
AUC O
and O
Cmaxincreased O
177 O
% O
and O
187 O
% O
respectively O
compared O
to O
administration O
of O
saquinavir O
alone O
. O

Clarithromycin O
AUC O
and O
Cmaxincreased O
45 O
% O
and O
39 O
% O
respectively O
, O
whereas O
the O
14-OH O
clarithromycin O
AUC O
and O
Cmaxdecreased O
24 O
% O
and O
34 O
% O
respectively O
, O
compared O
to O
administration O
with O
clarithromycin O
alone O
. O

No O
dose O
adjustment O
of O
clarithromycin O
is O
necessary O
when O
clarithromycin O
is O
co-administered O
with O
saquinavir O
in O
patients O
with O
normal O
renal O
function O
. O

When O
saquinavir O
is O
co-administered O
with O
ritonavir O
, O
consideration O
should O
be O
given O
to O
the O
potential O
effects O
of O
ritonavir O
on O
clarithromycin O
( O
refer O
to O
interaction O
between O
clarithromycin O
and O
ritonavir O
) O
( O
see O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

The O
following O
CYP3A O
based O
drug O
interactions O
have O
been O
observed O
with O
erythromycin O
products O
and/or O
with O
clarithromycin O
in O
post-marketing O
experience O
: O
Antiarrhythmics O
There O
have O
been O
post-marketing O
reports O
of O
torsades B-NonOSE_AE
de I-NonOSE_AE
pointes I-NonOSE_AE
occurring O
with O
concurrent O
use O
of O
clarithromycin O
and O
quinidine O
or O
disopyramide O
. O

Electrocardiograms O
should O
be O
monitored O
for O
QTc B-NonOSE_AE
prolongation I-NonOSE_AE
during O
coadministration O
of O
clarithromycin O
with O
these O
drugs O
. O

Serum O
concentrations O
of O
these O
medications O
should O
also O
be O
monitored O
. O

Ergotamine/Dihydroergotamine O
Post-marketing O
reports O
indicate O
that O
coadministration O
of O
clarithromycin O
with O
ergotamine O
or O
dihydroergotamine O
has O
been O
associated O
with O
acute B-NonOSE_AE
ergot I-NonOSE_AE
toxicity I-NonOSE_AE
characterized O
by O
vasospasm B-NonOSE_AE
and O
ischemia B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
extremities I-NonOSE_AE
and O
other O
tissues O
including O
the O
central O
nervous O
system O
. O

Concomitant O
administration O
of O
clarithromycin O
with O
ergotamine O
or O
dihydroergotamine O
is O
contraindicated O
( O
see O
CONTRAINDICATIONS O
) O
. O

Triazolobenziodidiazepines O
( O
Such O
as O
Triazolam O
and O
Alprazolam O
) O
and O
Related O
Benzodiazepines O
( O
Such O
as O
Midazolam O
) O
Erythromycin O
has O
been O
reported O
to O
decrease O
the O
clearance O
of O
triazolam O
and O
midazolam O
, O
and O
thus O
, O
may O
increase O
the O
pharmacologic O
effect O
of O
these O
benzodiazepines O
. O

There O
have O
been O
post-marketing O
reports O
of O
drug O
interactions O
and O
CNS B-NonOSE_AE
effects I-NonOSE_AE
( O
e.g. O
, O
somnolence B-NonOSE_AE
and O
confusion B-NonOSE_AE
) O
with O
the O
concomitant O
use O
of O
clarithromycin O
and O
triazolam O
. O

Sildenafil O
( O
Viagra O
) O
Erythromycin O
has O
been O
reported O
to O
increase O
the O
systemic O
exposure O
( O
AUC O
) O
of O
sildenafil O
. O

A O
similar O
interaction O
may O
occur O
with O
clarithromycin O
; O
reduction O
of O
sildenafil O
dosage O
should O
be O
considered O
. O

( O
See O
Viagra O
package O
insert O
. O
) O

There O
have O
been O
spontaneous O
or O
published O
reports O
of O
CYP3A O
based O
interactions O
of O
erythromycin O
and/or O
clarithromycin O
with O
cyclosporine O
, O
carbamazepine O
, O
tacrolimus O
, O
alfentanil O
, O
disopyramide O
, O
rifabutin O
, O
quinidine O
, O
methylprednisolone O
, O
cilostazol O
, O
bromocriptine O
and O
vinblastine O
. O

Concomitant O
administration O
of O
clarithromycin O
with O
cisapride O
, O
pimozide O
, O
astemizole O
, O
or O
terfenadine O
is O
contraindicated O
( O
see O
CONTRAINDICATIONS O
. O
) O

In O
addition O
, O
there O
have O
been O
reports O
of O
interactions O
of O
erythromycin O
or O
clarithromycin O
with O
drugs O
not O
thought O
to O
be O
metabolized O
by O
CYP3A O
, O
including O
hexobarbital O
, O
phenytoin O
, O
and O
valproate O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
The O
following O
in O
vitro O
mutagenicity O
tests O
have O
been O
conducted O
with O
clarithromycin O
: O
Salmonella O
/Mammalian O
Microsomes O
Test O
Bacterial O
Induced O
Mutation O
Frequency O
Test O
In O
Vitro O
Chromosome O
Aberration O
Test O
Rat O
Hepatocyte O
DNA O
Synthesis O
Assay O
Mouse O
Lymphoma O
Assay O
Mouse O
Dominant O
Lethal O
Study O
Mouse O
Micronucleus O
Test O
All O
tests O
had O
negative O
results O
except O
the O
In O
Vitro O
Chromosome O
Aberration O
Test O
which O
was O
weakly O
positive O
in O
one O
test O
and O
negative O
in O
another O
. O

In O
addition O
, O
a O
Bacterial O
Reverse-Mutation O
Test O
( O
Ames O
Test O
) O
has O
been O
performed O
on O
clarithromycin O
metabolites O
with O
negative O
results O
. O

Fertility O
and O
reproduction O
studies O
have O
shown O
that O
daily O
doses O
of O
up O
to O
160 O
mg/kg/day O
( O
1.3 O
times O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
) O
to O
male O
and O
female O
rats O
caused O
no O
adverse O
effects O
on O
the O
estrous O
cycle O
, O
fertility O
, O
parturition O
, O
or O
number O
and O
viability O
of O
offspring O
. O

Plasma O
levels O
in O
rats O
after O
150 O
mg/kg/day O
were O
2 O
times O
the O
human O
serum O
levels O
. O

In O
the O
150 O
mg/kg/day O
monkey O
studies O
, O
plasma O
levels O
were O
3 O
times O
the O
human O
serum O
levels O
. O

When O
given O
orally O
at O
150 O
mg/kg/day O
( O
2.4 O
times O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
) O
, O
clarithromycin O
was O
shown O
to O
produce O
embryonic B-NonOSE_AE
loss I-NonOSE_AE
in O
monkeys O
. O

This O
effect O
has O
been O
attributed O
to O
marked O
maternal B-NonOSE_AE
toxicity I-NonOSE_AE
of O
the O
drug O
at O
this O
high O
dose O
. O

In O
rabbits O
, O
in O
utero O
fetal B-NonOSE_AE
loss I-NonOSE_AE
occurred O
at O
an O
intravenous O
dose O
of O
33 O
mg/m O
2 O
, O
which O
is O
17 O
times O
less O
than O
the O
maximum O
proposed O
human O
oral O
daily O
dose O
of O
618 O
mg/m O
2 O
. O

Long-term O
studies O
in O
animals O
have O
not O
been O
performed O
to O
evaluate O
the O
carcinogenic O
potential O
of O
clarithromycin O
. O

Pregnancy O
Teratogenic O
Effects O
Pregnancy O
Category O
C O
Four O
teratogenicity B-NonOSE_AE
studies O
in O
rats O
( O
three O
with O
oral O
doses O
and O
one O
with O
intravenous O
doses O
up O
to O
160 O
mg/kg/day O
administered O
during O
the O
period O
of O
major O
organogenesis O
) O
and O
two O
in O
rabbits O
at O
oral O
doses O
up O
to O
125 O
mg/kg/day O
( O
approximately O
2 O
times O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
) O
or O
intravenous O
doses O
of O
30 O
mg/kg/day O
administered O
during O
gestation O
days O
6 O
to O
18 O
failed O
to O
demonstrate O
any O
teratogenicity B-NonOSE_AE
from O
clarithromycin O
. O

Two O
additional O
oral O
studies O
in O
a O
different O
rat O
strain O
at O
similar O
doses O
and O
similar O
conditions O
demonstrated O
a O
low O
incidence O
of O
cardiovascular B-NonOSE_AE
anomalies I-NonOSE_AE
at O
doses O
of O
150 O
mg/kg/day O
administered O
during O
gestation O
days O
6 O
to O
15 O
. O

Plasma O
levels O
after O
150 O
mg/kg/day O
were O
2 O
times O
the O
human O
serum O
levels O
. O

Four O
studies O
in O
mice O
revealed O
a O
variable O
incidence O
of O
cleft B-NonOSE_AE
palate I-NonOSE_AE
following O
oral O
doses O
of O
1000 O
mg/kg/day O
( O
2 O
and O
4 O
times O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
, O
respectively O
) O
during O
gestation O
days O
6 O
to O
15 O
. O

Cleft B-NonOSE_AE
palate I-NonOSE_AE
was O
also O
seen O
at O
500 O
mg/kg/day O
. O

The O
1000 O
mg/kg/day O
exposure O
resulted O
in O
plasma O
levels O
17 O
times O
the O
human O
serum O
levels O
. O

In O
monkeys O
, O
an O
oral O
dose O
of O
70 O
mg/kg/day O
( O
an O
approximate O
equidose O
of O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
) O
produced O
fetal B-NonOSE_AE
growth I-NonOSE_AE
retardation I-NonOSE_AE
at O
plasma O
levels O
that O
were O
2 O
times O
the O
human O
serum O
levels O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

Clarithromycin O
should O
be O
used O
during O
pregnancy B-NonOSE_AE
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
fetus I-NonOSE_AE
. O

( O
See O
WARNINGS O
. O
) O

Nursing O
Mothers O
It O
is O
not O
known O
whether O
clarithromycin O
is O
excreted O
in O
human O
milk O
. O

Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
, O
caution O
should O
be O
exercised O
when O
clarithromycin O
is O
administered O
to O
a O
nursing O
woman O
. O

It O
is O
known O
that O
clarithromycin O
is O
excreted O
in O
the O
milk O
of O
lactating O
animals O
and O
that O
other O
drugs O
of O
this O
class O
are O
excreted O
in O
human O
milk O
. O

Preweaned O
rats O
, O
exposed O
indirectly O
via O
consumption O
of O
milk O
from O
dams O
treated O
with O
150 O
mg/kg/day O
for O
3 O
weeks O
, O
were O
not O
adversely O
affected O
, O
despite O
data O
indicating O
higher O
drug O
levels O
in O
milk O
than O
in O
plasma O
. O

Pediatric O
Use O
Safety O
and O
effectiveness O
of O
clarithromycin O
in O
pediatric O
patients O
under O
6 O
months O
of O
age O
have O
not O
been O
established O
. O

The O
safety O
of O
clarithromycin O
has O
not O
been O
studied O
in O
MAC B-Not_AE_Candidate
patients O
under O
the O
age O
of O
20 O
months O
. O

Neonatal O
and O
juvenile O
animals O
tolerated O
clarithromycin O
in O
a O
manner O
similar O
to O
adult O
animals O
. O

Young O
animals O
were O
slightly O
more O
intolerant O
to O
acute O
overdosage O
and O
to O
subtle O
reductions B-NonOSE_AE
in I-NonOSE_AE
erythrocytes I-NonOSE_AE
, O
platelets O
and O
leukocytes O
but O
were O
less O
sensitive O
to O
toxicity O
in O
the O
liver O
, O
kidney O
, O
thymus O
, O
and O
genitalia O
. O

Geriatric O
Use O
In O
a O
steady-state O
study O
in O
which O
healthy O
elderly O
subjects O
( O
age O
65 O
to O
81 O
years O
old O
) O
were O
given O
500 O
mg O
every O
12 O
hours O
, O
the O
maximum O
serum O
concentrations O
and O
area O
under O
the O
curves O
of O
clarithromycin O
and O
14-OH O
clarithromycin O
were O
increased O
compared O
to O
those O
achieved O
in O
healthy O
young O
adults O
. O

These O
changes O
in O
pharmacokinetics O
parallel O
known O
age-related O
decreases B-NonOSE_AE
in I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

In O
clinical O
trials O
, O
elderly O
patients O
did O
not O
have O
an O
increased O
incidence O
of O
adverse O
events O
when O
compared O
to O
younger O
patients O
. O

Dosage O
adjustment O
should O
be O
considered O
in O
elderly O
patients O
with O
severe B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

( O
See O
WARNINGS O
and O
PRECAUTIONS O
. O
) O

